EUVIMEDEUVIMED entdecken
Vergleichsstudie

Deescalated 225 Ac-PSMA-617 Versus 177 Lu/ 225 Ac-PSMA-617 Cocktail Therapy: A Single-Center Retrospective Analysis of 233 Patients

Hendrik Rathke, Erik Winter, Frank Bruchertseifer, Manuel Röhrich, Frederik Lars Giesel, Uwe Haberkorn, Alfred Morgenstern, Clemens Kratochwil

Journal of Nuclear Medicine · 2024-07 · 65 (7) · 1057-1063

DOI: 10.2967/jnumed.123.267206 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 06.06.2024. Verfasst von Hendrik Rathke und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany; hendrik.rathke@ksgr.ch. Hauptthemen laut MEDLINE: Dipeptides, Lutetium, Heterocyclic Compounds, 1-Ring, Actinium. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The aim of this work is to evaluate our clinical real-world data obtained with 225Ac-PSMA-617 (AcPSMA), which were acquired under compassionate care regulations in patients with advanced-stage prostate cancer. The objective parameters that could be derived from this evaluation are compared with previous literature about AcPSMA and 177Lu-PSMA-617 (LuPSMA).

Methods

The medical files of all patients who had received AcPSMA on an individual patient basis at the Heidelberg University Hospital since January 2014 were analyzed retrospectively. Previously published patients were excluded. The remaining patients were tailored into 2 subgroups with different treatment strategies: group 1 received AcPSMA as a deescalated monotherapy, and group 2 received LuPSMA plus AcPSMA as a cocktail regimen. Baseline characteristics, serum prostate-specific antigen (PSA) response, and overall survival were compared with the most appropriate historical controls.

Results

Of 287 patients treated, 54 were excluded because of previous publication and 233 were evaluated, 104 of whom received AcPSMA monotherapy (median, 6 MBq). In this group, 55 patients (53%) presented with a best PSA response of at least 50%. The other 129 patients received a cocktail therapy of AcPSMA (median, 4 MBq) plus LuPSMA (4 GBq). In this group, a best PSA response of at least 50% was observed in 74 patients (57%). The median overall survival in the monogroup was 9 mo and in the cocktail group was 15 mo. If adjusted for prognostic baseline characteristics, the efficacy of both regimens was not significantly different.

Conclusion

Deescalated treatment activities of AcPSMA or AcPSMA and LuPSMA cocktail regimens present better tolerability with regard to xerostomia than previous regimens of at least 100 kBq/kg while retaining high antitumor activity in poor-prognosis prostate cancer patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DipeptidesLutetiumHeterocyclic Compounds, 1-RingActiniumHumansMaleRetrospective StudiesAgedMiddle AgedProstatic NeoplasmsProstate-Specific AntigenAged, 80 and overTreatment OutcomeRadiopharmaceuticals

Stichwörter der Autor:innen

177Lu225AcPSMATATcocktailmCRPC

Substanzen

DipeptidesLutetiumHeterocyclic Compounds, 1-RingActinium(225)Ac-PSMA-617Prostate-Specific AntigenPluvictoRadiopharmaceuticals

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany; hendrik.rathke@ksgr.ch.
  • Department of Nuclear Medicine, Bern University Hospital, Bern, Switzerland.
  • Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany.
  • Joint Research Centre, European Commission, Karlsruhe, Germany.
  • Department of Nuclear Medicine, Mainz University Hospital, Mainz, Germany; and.
  • Department of Nuclear Medicine, University Hospital Duesseldorf, Duesseldorf, Germany.

Zitieren

APA

Rathke, H., Winter, E., Bruchertseifer, F., Röhrich, M., Giesel, F. L., Haberkorn, U., Morgenstern, A., & Kratochwil, C. (2024). Deescalated 225 Ac-PSMA-617 Versus 177 Lu/ 225 Ac-PSMA-617 Cocktail Therapy: A Single-Center Retrospective Analysis of 233 Patients. Journal of Nuclear Medicine, 65(7), 1057-1063. https://doi.org/10.2967/jnumed.123.267206

Vancouver

Rathke H, Winter E, Bruchertseifer F, Röhrich M, Giesel FL, Haberkorn U, et al. Deescalated 225 Ac-PSMA-617 Versus 177 Lu/ 225 Ac-PSMA-617 Cocktail Therapy: A Single-Center Retrospective Analysis of 233 Patients. Journal of Nuclear Medicine. 2024;65(7):1057-1063. doi:10.2967/jnumed.123.267206

BibTeX
@article{Rathke2024,
  author = {Rathke, Hendrik and Winter, Erik and Bruchertseifer, Frank and Röhrich, Manuel and Giesel, Frederik Lars and Haberkorn, Uwe and Morgenstern, Alfred and Kratochwil, Clemens},
  title = {Deescalated 225 Ac-PSMA-617 Versus 177 Lu/ 225 Ac-PSMA-617 Cocktail Therapy: A Single-Center Retrospective Analysis of 233 Patients},
  journal = {Journal of Nuclear Medicine},
  year = {2024},
  volume = {65},
  number = {7},
  pages = {1057--1063},
  doi = {10.2967/jnumed.123.267206}
}
Kostenlos starten →